Dataset Information

Study of Turbulence Promoters in Prolonging Membrane Life.

ABSTRACT: Nanofiltration membrane technology is an effective method for secondary treated sewage purification. However, membrane fouling, which is inevitable in the membrane-separation process, can reduce membrane performance and shorten membrane life. Installing a turbulence promoter is a promising means of improving the hydraulic conditions inside the membrane chamber. In this study, the effect of turbulence promoter on prolonging membrane life was studied for the first time. Flat-sheet polyethersulfone nanofiltration membrane was used to filter humic acid solution, used for simulating secondary treated sewage. By comparing photographs and SEM images of the membrane before and after the simulated secondary treated sewage filtration, it was found that humic acid tended to be deposited on the low-velocity region, which was reflected by COMSOL simulation. After incorporating a turbulence promoter, the reduction of the humic acid deposition area and membrane fouling resistance indicated that the turbulence promoter could reduce membrane fouling due to the improved hydraulic conditions. Additionally, the turbulence promoter also increased the flux and reduced the flux decay rate. The turbulence promoter was then place in the crossflow flat-sheet membrane filtration module, and the variation of flux with time was tested in simulated secondary treated sewage with different concentrations. The results showed that the membrane life for the filtration of simulated secondary treated sewage comprising 50, 250, and 500 ppm humic acid increased by 23.1%, 80.4%, and 85.7%, respectively. The results of this article can serve as a reference for the prediction of membrane life and the performance enhancement mechanism of membranes containing a turbulence promoter.

SUBMITTER: Jiang B

PROVIDER: S-EPMC8068148 | biostudies-literature |

REPOSITORIES: biostudies-literature

ACCESS DATA

Similar Datasets

Project description:BackgroundAntineoplastic therapy may impair the survival of malignant cells to produce cell death. Consequently, direct measurement of tumor cell death in vivo is a highly desirable component of therapy response monitoring. We have previously shown that APOMAB representing the DAB4 clone of a La/SSB-specific murine monoclonal autoantibody is a malignant cell-death ligand, which accumulates preferentially in tumors in an antigen-specific and dose-dependent manner after DNA-damaging chemotherapy. Here, we aim to image tumor uptake of APOMAB (DAB4) and to define its biological correlates.Methodology/principal findingsBrisk tumor cell apoptosis is induced in the syngeneic EL4 lymphoma model after treatment of tumor-bearing mice with DNA-damaging cyclophosphamide/etoposide chemotherapy. Tumor and normal organ accumulation of Indium 111 ((111)In)-labeled La-specific DAB4 mAb as whole IgG or IgG fragments was quantified by whole-body static imaging and organ assay in tumor-bearing mice. Immunohistochemical measurements of tumor caspase-3 activation and PARP-1 cleavage, which are indicators of early and late apoptosis, respectively, were correlated with tumor accumulation of DAB4. Increased tumor accumulation of DAB4 was associated directly with both the extent of chemotherapy-induced tumor cell death and DAB4 binding per dead tumor cell. Tumor DAB4 accumulation correlated with cumulative caspase-3 activation and PARP-1 cleavage as tumor biomarkers of apoptosis and was directly related to the extended median survival time of tumor-bearing mice.Conclusions/significanceRadiolabeled La-specific monoclonal antibody, DAB4, detected dead tumor cells after chemotherapy, rather than chemosensitive normal tissues of gut and bone marrow. DAB4 identified late apoptotic tumor cells in vivo. Hence, radiolabeled DAB4 may usefully image responses to human carcinoma therapy because DAB4 would capture the protracted cell death of carcinoma. We believe that the ability of radiolabeled DAB4 to rapidly assess the apoptotic tumor response and, consequently, to potentially predict extended survival justifies its future clinical development as a radioimmunoscintigraphic agent. This article is part I of a two-part series providing proof-of-concept for the the diagnostic and therapeutic use of a La-specific monoclonal antibody, the DAB4 clone of which is represented by the registered trademark, APOMAB.

Dataset Information

Study of Turbulence Promoters in Prolonging Membrane Life.

Similar Datasets

OmicsDI is part of the ELIXIR infrastructure

Tweets